When should PSVD be suspected - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The talk provides valuable clinical insights for diagnosing PSVD, a rare and underrecognized condition. The argumentation is solid, based on data from multiple cohorts and studies, and acknowledges limitations such as the high prevalence of PSVD in tertiary centers affecting predictive values. The speaker effectively uses comparative data to illustrate key points, such as the contrast between liver and spleen stiffness in PSVD versus cirrhosis. The discussion with the audience adds depth, addressing practical concerns like biopsy indications and the need for broader education. However, some claims rely on unpublished data or personal experience, and the lack of a systematic review limits the strength of conclusions.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor by referencing specific cohorts (e.g., VALDIG, Chinese cohort) and studies, and by discussing diagnostic criteria. The sources cited are primarily from the speaker’s own research and collaborative networks, which are credible in the field. The title accurately reflects the content, focusing on clinical suspicion. However, the talk is an expert opinion rather than a systematic review, and some data are not fully referenced in the video. The audience questions and responses further illustrate the scientific debate, but no formal citations are provided for all claims.

The title accurately reflects the content, which focuses on clinical scenarios and tools for suspecting PSVD.

8/10

Presentation by a recognized expert in hepatology, based on clinical cohorts and recent studies, with clear methodology and discussion of limitations. However, it is an expert opinion and not a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction: challenge of diagnosing rare disease, need for tools.
• 03:00Clinical scenario 1: portal hypertension with preserved liver function.
• 06:00Associated conditions and causes of chronic liver disease, including HBV.
• 09:00Liver stiffness measurement: low values in PSVD vs cirrhosis.
• 12:00Combination of liver and spleen stiffness for diagnosis.
• 15:00Cross-sectional imaging features: smooth liver surface, normal segment 4.
• 18:00Scenario 2: patients without portal hypertension, elevated GGT.
• 21:00Metabolomics as a potential future tool.
• 24:00Summary and recommendations.

• FILFOIE website — Network organizing the meeting and providing resources on rare liver diseases.

• VALDIG cohort study — European cohort providing data on clinical features of PSVD.